// App-Quantinova.ai

3028 : Clinical Significance of Addition of Cytarabine or Thiotepa to TBI/CY Regimen.

Researchers

Presenter

  • Masatsugu Tanaka

Principal Investigators

  • Maki Hagihara

  • Shin Fujisawa

  • Atsuo Maruta

  • Yoshiaki Ishigatsubo

  • Heiwa Kanamori

  • Rika Ohshima

  • Etsuko Yamazaki

  • Hideyuki Koharazawa

  • Jun Taguchi

  • Naoto Tomita

  • Katsumichi Fujimaki

  • Rika Sakai

  • Hiroyuki Fujita

Medical Centers

  • Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan

  • Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan

  • of Hematology, Kanagawa Cancer Center, Yokohama, Japan

  • Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Graft-versus-host disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Cytarabine liposomal

  • Thiotepa

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved